Page last updated: 2024-12-08
4-trifluoromethylsalicylic acid
Description
Research Excerpts
Clinical Trials
Roles
Classes
Pathways
Study Profile
Bioassays
Related Drugs
Related Conditions
Protein Interactions
Research Growth
Market Indicators
Description
4-trifluoromethylsalicylic acid: structure given in first source; metabolite of triflusal [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
Cross-References
| ID Source | ID |
|---|---|
| PubMed CID | 164578 |
| CHEMBL ID | 3244577 |
| CHEBI ID | 174020 |
| SCHEMBL ID | 115659 |
| MeSH ID | M0103900 |
Synonyms (47)
| Synonym |
|---|
| 2-hydroxy-4-trifluoromethyl benzoic acid |
| 2-hydroxy-4-(triluoromethyl)benzoic acid |
| CHEBI:174020 |
| STK377474 |
| 2-hydroxy-4-(trifluoromethyl)benzoic acid |
| 4-trifluoromethylsalicylic acid |
| T2064 |
| 328-90-5 |
| 4-(trifluoromethyl)salicylic acid |
| AKOS003368342 |
| 2-hydroxy-4-trifluoromethylbenzoic acid |
| benzoic acid, 2-hydroxy-4-(trifluoromethyl)- |
| 4-tfmsa |
| uky7yre9e9 , |
| unii-uky7yre9e9 |
| FT-0601285 |
| 4-trifluoromethyl salicylic acid |
| c8h5f3o3 |
| desacetyl triflusal-13c6 |
| p-(trifluoromethyl)salicylic acid |
| 4-trifluoromethyl-2-hydroxybenzoic acid |
| 2-hydroxy-4-trifluoromethyl-benzoic acid |
| CHEMBL3244577 |
| SCHEMBL115659 |
| AM84126 |
| FS-2331 |
| 4-trifluoromethylsalicylicacid |
| 4-trifluoro methyl salicylic acid |
| mfcd01529657 |
| desacetyl triflusal |
| J-509625 |
| 2-hydroxy-4-(trifluoromethyl)benzoic acid, aldrichcpr |
| DTXSID00186474 |
| AC-8128 |
| 1246817-12-8 |
| 2-hydroxy-4-(trifluoromethyl)benzoic acid (4-(trifluoromethyl)salicylic acid) |
| SY002112 |
| CS-W015348 |
| BCP24443 |
| triflusal impurity b |
| SB36620 |
| triflusal impurity b [ep impurity] |
| EN300-126593 |
| BKA30032 |
| HY-W014632 |
| desacetyltriflusal-13c6 |
| Z1269108938 |
Research Excerpts
Toxicity
| Excerpt | Reference | Relevance |
|---|---|---|
| "An enteric-coated formulation of triflusal (triflusal EC), an antiplatelet agent, was developed to reduce the high incidence of gastrointestinal adverse events (AEs)." | ( A phase I study to characterize the multiple-dose pharmacokinetics, pharmacodynamics and safety of new enteric-coated triflusal formulations in healthy male volunteers. Baek, IH; Kwon, KI; Lee, HW; Lee, J; Lim, MS; Park, J; Seo, JJ; Seong, SJ; Yoon, YR; Yun, HY, 2011) | 0.37 |
| " Safety was assessed by adverse events, ECG, laboratory testing, and vital signs." | ( Pharmacokinetics, safety and tolerability of triflusal and its main active metabolite HTB in healthy Chinese subjects. Hua, W; Huang, M; Wang, M; Zhang, Q; Zhou, W; Zong, S, 2014) | 0.4 |
Pharmacokinetics
Dosage Studied
| Excerpt | Relevance | Reference |
|---|---|---|
| "ss) during the multiple dosage regimen of 300 mg every 8 h, and 131 micrograms." | ( Binding of a metabolite of triflusal (2-hydroxy-4-trifluoromethylbenzoic acid) to serum proteins in rat and man. Conte, L; Forn, J; Mis, R; Ramis, J, 1992) | 0.28 |
| "Triflusal pharmacokinetics were evaluated in 8 healthy subjects after a single 300 mg dose and after repeated doses of 300 mg every 8 h and 600 mg every 24 h during 13 days, with the aim of establishing a relationship between plasma levels and dosage patterns." | ( Pharmacokinetics of triflusal after single and repeated doses in man. Barbanoj, MJ; Conte, L; Forn, J; Jané, J; Mis, R; Ramis, J; Torrent, J, 1990) | 0.28 |
| "Following oral dosing under fasting condition, triflusal is promptly absorbed and rapidly depleted from the systemic circulation." | ( Pharmacokinetics, safety and tolerability of triflusal and its main active metabolite HTB in healthy Chinese subjects. Hua, W; Huang, M; Wang, M; Zhang, Q; Zhou, W; Zong, S, 2014) | 0.4 |
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
Drug Classes (1)
| Class | Description |
|---|---|
| hydroxybenzoic acid | Any benzoic acid carrying one or more phenolic hydroxy groups on the benzene ring. |
| [compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] | |
Bioassays (1)
| Assay ID | Title | Year | Journal | Article |
|---|---|---|---|---|
| AID1136197 | Antiinflammatory activity against carrageenan-induced foot edema in rat at 400 mg/kg administered via gastric gavage | 1978 | Journal of medicinal chemistry, Nov, Volume: 21, Issue:11 | Novel analgesic-antiinflammatory salicylates. |
| [information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||||
Research
Studies (45)
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 5 (11.11) | 18.7374 |
| 1990's | 6 (13.33) | 18.2507 |
| 2000's | 11 (24.44) | 29.6817 |
| 2010's | 6 (13.33) | 24.3611 |
| 2020's | 17 (37.78) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
Market Indicators
Research Demand Index: 11.18
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| This Compound (11.18) All Compounds (24.57) |
Study Types
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 5 (10.87%) | 5.53% |
| Reviews | 1 (2.17%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 1 (2.17%) | 0.25% |
| Other | 39 (84.78%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||